Real-world utilization and acceptance of biosimilar bevacizumab in metastatic colorectal cancer in India

Background: To describe the patient characteristics and usage pattern of biosimilar bevacizumab for treatment metastatic colorectal cancer (mCRC) in India.Methods: This real-world, retrospective analysis included adult patients receiving between April 2021 March 2022.Results: A total 1125 with mCRC who received bevacizumab-based chemotherapy were included. The mean age at diagnosis was 57.8 years. Majority males (71%) belonged to groups 41-76 primary tumor site right colon (52.6%) followed by left (29.2%) rectum (17.3%), grade reported as high most (88.7%) patients. first-line therapy (61.3%), second-line (31.9%) third-line (6.8%). In combination bevacizumab, FOLFOX (folinic acid, 5-fluorouracil, oxaliplatin) commonly administered regimen (42.9%), CAPOX (capecitabine oxaliplatin, 26.5%) FOLFIRI irinotecan, 22.8%).Conclusions: Biosimilar is being widely used real‑world clinical setting India management mCRC.